Written Question·Department of Health and Social Care·UIN 87906

Abiraterone: Finance

Tabled: 4 November 2025

Answered: 17 November 2025

Question

Mr Louie French

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2025 to Question 83371 on Abiraterone: Finance, what steps he is taking to secure recurrent budget allocation for abiraterone for use in cases of high-risk non-

Answer

Dr Zubir Ahmed

Abiraterone is not licensed for use in the treatment of high-risk, non-metastatic hormone-sensitive prostate cancer, and as such, cannot be evaluated by the National Institute for Health and Care Excellence (NICE) for routine use on the National Health Se...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 87906) →